Tigecycline Crystalline Forms for Stability and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Tigecycline, an antibiotic effective against drug-resistant bacteria, has poor bioavailability when administered orally and requires expensive low-oxygen, low-temperature processing due to its propensity to degrade, making crystalline solid forms more stable and easier to manufacture than its amorphous counterparts.
Innovation Solution
Identification and characterization of crystalline solid forms of tigecycline (Forms I, II, III, IV, and V) using X-ray powder diffraction and other analytical techniques, along with processes for preparing these forms, including slurry methods with organic solvents to convert one form into another, facilitating stable and cost-effective production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If tigecycline is processed under low-oxygen and low-temperature conditions to prevent degradation, then stability is improved, but manufacturing cost and device complexity increase
Solution Approach 1:
The patent changes the physical state parameter of tigecycline from amorphous to crystalline form. This parameter change fundamentally alters the stability characteristics, allowing the compound to maintain stability without requiring special low-oxygen and low-temperature processing conditions. The crystalline structure inherently provides greater stability, eliminating the need for complex handling systems.
Solution Approach 2:
The patent utilizes phase transition from amorphous to crystalline state. By inducing crystallization through specific solvents and temperature conditions during manufacturing, the patent transforms tigecycline into a more stable crystalline form that does not require special processing conditions for storage and handling, thereby reducing device complexity while maintaining stability.
2Ease of operation
If tigecycline is administered orally, then ease of administration is improved, but bioavailability decreases
Solution Approach 1:
The patent changes the physical state parameter from amorphous to crystalline form, which improves solubility and dissolution characteristics. This parameter change enhances bioavailability when administered orally, making the drug more reliable while maintaining ease of administration. The crystalline forms exhibit improved pharmacokinetic properties compared to the amorphous form.
3Ease of manufacture
If amorphous powder is used for tigecycline, then ease of manufacture is improved, but stability decreases
Solution Approach 1:
The patent employs phase transition from amorphous to crystalline state through controlled crystallization processes using specific solvents and temperature conditions. This transition maintains ease of manufacture through established crystallization techniques while dramatically improving stability, as crystalline forms are inherently more stable than amorphous forms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline solid forms of tigecycline offer improved stability and handling properties, potentially allowing for oral administration without the need for special handling systems, enhancing bioavailability and reducing production costs.
Implementation Method 1
X-ray powder diffraction is a suitable technique for differentiating amorphous solid forms from crystalline solid forms and for characterizing and identifying crystalline solid forms of a compound
Implementation Method 2
When the same molecule, such as an organic molecule, can order itself in a solid in more than one way, that molecule exhibits what is called polymorphism
Implementation Method 3
Crystalline compounds are solids with ordered arrays of molecules, whereas amorphous compounds are composed of disordered molecules. These arrays are also termed crystal lattices and are composed of repeating structural segments called unit cells
Implementation Method 4
Sometimes solvent or water molecules become incorporated into the crystal lattice of a crystalline solid. Such a crystalline solid may be referred to as a solvate or hydrate, respectively
Data Source
AI summary
Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.